Table II.
Organization of the groups in the present study.
| Determination of IFN-γ-producing CTLs by ELISPOT | Lethal effect of CTLs in vitro | Establishment of pancreatic cancer in mice | Treatment of tumor-bearing mice |
|---|---|---|---|
| Empty vector group | Empty vector group | Empty vector group | Empty vector group |
| Weak VNTR1 group | HeLa cells group | Panc02 control group | Panc02 control group |
| Strong VNTR1 group | Weak VNTR1 group | Weak VNTR1 group | Weak VNTR1 group |
| VNTR3 group | Strong VNTR1 group | Strong VNTR1 group | Strong VNTR1 group |
| VNTR4 group | VNTR3 group | VNTR3 group | VNTR3 group |
| VNTR6 group | VNTR4 group | VNTR4 group | VNTR4 group |
| VNTR9 group | VNTR6 group | VNTR6 group | VNTR6 group |
| MUC1-cDNA group | VNTR9 group MUC1-cDNA group | VNTR9 group | VNTR9 group |
Weak VNTR1, single VNTR repetitive sequence with weak immunogenicity; Strong VNTR1, single VNTR repetitive sequence with strong immunogenicity; VNTR3, strong VNTR1 with 3 repeats; VNTR4, strong VNTR1 with 4 repeats; VNTR6, strong VNTR1 with 6 repeats; VNTR9, strong VNTR1 with 9 repeats; MUC1, mucin 1; CTLs, cytotoxic T lymphocytes.